biote Corp. Stock

Equities

BTMD

US0906831039

Professional Information Services

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
5.52 USD -1.08% Intraday chart for biote Corp. -0.36% +11.74%
Sales 2024 * 202M Sales 2025 * 234M Capitalization 191M
Net income 2024 * 19M Net income 2025 * 26M EV / Sales 2024 * 1.14 x
Net Debt 2024 * 39.68M Net Debt 2025 * 14.7M EV / Sales 2025 * 0.88 x
P/E ratio 2024 *
27.6 x
P/E ratio 2025 *
13.8 x
Employees 194
Yield 2024 *
-
Yield 2025 *
-
Free-Float 71.98%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.08%
1 week-0.36%
Current month-4.83%
1 month-5.96%
3 months+38.00%
6 months+8.02%
Current year+11.74%
More quotes
1 week
5.40
Extreme 5.4
5.80
1 month
5.30
Extreme 5.3
6.22
Current year
3.65
Extreme 3.6538
7.50
1 year
3.65
Extreme 3.6538
8.22
3 years
2.00
Extreme 2
10.53
5 years
2.00
Extreme 2
10.53
10 years
2.00
Extreme 2
10.53
More quotes
Managers TitleAgeSince
Chief Executive Officer 71 22-04-30
Chief Tech/Sci/R&D Officer 62 19-05-31
Chief Tech/Sci/R&D Officer 52 22-06-09
Members of the board TitleAgeSince
Director/Board Member 70 22-04-30
Director/Board Member 66 22-04-30
Chairman 59 22-04-30
More insiders
Date Price Change Volume
24-04-26 5.52 -1.08% 68,915
24-04-25 5.58 -0.18% 42,029
24-04-24 5.59 +0.36% 21,048
24-04-23 5.57 +0.36% 54,058
24-04-22 5.55 +0.18% 63,426

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT

More quotes
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.52 USD
Average target price
8.648 USD
Spread / Average Target
+56.67%
Consensus